— Research and development expenses dropped to $12.3 million in the fourth quarter from $22.9 million last year
— Established research collaboration with the University of Queensland and the Coalition for Epidemic Preparedness to develop coronavirus vaccine
— Appointed Ryan Spencer chief executive officer and to the board of directors; named David Novack president and chief operating officer
ADVERTISEMENT
— Expects HEPLISAV-B net product revenue to increase to $55-$62 million in fiscal 2020
— On track to release interim data from ongoing study of HEPLISAV-B in hemodialysis patients in the first quarter
Get access to timely and accurate verbatim transcripts that are published within hours of the event.